CATALOGO DEI PRODOTTI DELLA RICERCA

BRONTE, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.503
EU - Europa 6.308
AS - Asia 2.519
SA - Sud America 24
OC - Oceania 20
AF - Africa 16
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.393
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.465
GB - Regno Unito 2.799
CN - Cina 1.446
SG - Singapore 825
IT - Italia 631
RU - Federazione Russa 572
FR - Francia 498
IE - Irlanda 433
FI - Finlandia 417
DE - Germania 390
SE - Svezia 324
UA - Ucraina 132
VN - Vietnam 57
TR - Turchia 43
HK - Hong Kong 32
CA - Canada 30
ID - Indonesia 30
NL - Olanda 28
BE - Belgio 27
KR - Corea 21
AU - Australia 15
IN - India 15
JP - Giappone 14
BR - Brasile 12
CZ - Repubblica Ceca 11
ES - Italia 10
TG - Togo 9
CL - Cile 6
NZ - Nuova Zelanda 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
AT - Austria 4
AL - Albania 3
EC - Ecuador 3
HU - Ungheria 3
IL - Israele 3
LU - Lussemburgo 3
LV - Lettonia 3
MY - Malesia 3
NG - Nigeria 3
PL - Polonia 3
RO - Romania 3
TW - Taiwan 3
AM - Armenia 2
BY - Bielorussia 2
CH - Svizzera 2
CR - Costa Rica 2
EG - Egitto 2
EU - Europa 2
IR - Iran 2
JM - Giamaica 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
PA - Panama 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
CO - Colombia 1
DK - Danimarca 1
EE - Estonia 1
GL - Groenlandia 1
HR - Croazia 1
IQ - Iraq 1
JO - Giordania 1
LB - Libano 1
LK - Sri Lanka 1
MA - Marocco 1
MK - Macedonia 1
MN - Mongolia 1
MX - Messico 1
NO - Norvegia 1
OM - Oman 1
PH - Filippine 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 15.393
Salva come PNG Salva come JPEG
Città #
Southend 2.673
Jacksonville 1.241
Chandler 857
Woodbridge 851
Singapore 652
Ann Arbor 635
Houston 433
Dublin 424
Verona 309
Ashburn 308
Beijing 244
Lawrence 220
Princeton 220
Wilmington 216
Nanjing 132
Shenyang 116
New York 115
Jinan 112
Sindelfingen 84
Redmond 75
Helsinki 72
Hebei 66
Tianjin 62
Nanchang 55
Milan 52
Haikou 51
Ningbo 48
Hangzhou 44
Zhengzhou 44
Changsha 37
Los Angeles 37
Jiaxing 35
Taizhou 34
Guangzhou 31
Seattle 31
Norwalk 30
San Francisco 29
Dong Ket 27
Jakarta 27
Brussels 26
Boardman 25
Santa Clara 25
Taiyuan 25
Hong Kong 24
Toronto 24
Chicago 23
Redwood City 22
Dearborn 20
Fuzhou 20
Dongguan 19
Falls Church 19
Seoul 19
Moscow 16
Washington 16
Grafing 15
Fairfield 13
Munich 13
Dallas 12
Amsterdam 11
Düsseldorf 11
Lanzhou 11
Auburn Hills 9
Kochi 9
Lomé 9
San Diego 9
Cagliari 8
Cambridge 8
Padova 8
Tokyo 7
Bologna 6
Ferrara 6
Groningen 6
Mehlingen 6
Melbourne 6
San Giovanni Lupatoto 6
Auckland 5
Brno 5
Clearwater 5
Detroit 5
Großschönau 5
Isola della Scala 5
Kent 5
London 5
Riyadh 5
Shanghai 5
Bolzano 4
Canberra 4
Chengdu 4
Chions 4
Lappeenranta 4
Ottawa 4
Paris 4
Renton 4
Riva 4
Sydney 4
São Paulo 4
Tombolo 4
Trieste 4
Vienna 4
Boydton 3
Totale 11.350
Salva come PNG Salva come JPEG
Nome #
IFN-gamma- Mediated Upmodulation of MHC Class I Expression Activates Tumor-Specific Immune Response in a Mouse Model of Prostate Cancer 184
IFN-gamma- Mediated Upmodulation of MHC Class I Expression Associated to a B7-1-Expressing Tumor Cell Vaccine Activates Tumor-Specific Immune Response in a Mouse Model of Prostate Cancer. 169
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. 139
MAP Kinase inhibition reshapes tumour microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages 139
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma 129
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 128
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 121
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 120
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 118
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 116
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. 114
Human Anti Cancer Cytokine Induced Killer Cells and TheirInteraction With the Host Immune System 113
Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy 110
Role of P2z purinergic receptors in ATP-mediated killing of tumor necrosis factor (TNF)-sensitive and TNF-resistant L929 fibroblasts. 109
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer 107
MDSCs in cancer: Conceiving new prognostic and therapeutic targets 105
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 103
Unraveling the role of lymph node metastasis in PDAC and dCCA progression 103
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. 102
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). 99
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. 99
Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins 99
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 99
The Emerging Immunological Role of Post-Translational Modifications by Reactive Nitrogen Species in Cancer Microenvironment 98
New idrosoluble furoxan derivatives having antitumoral activity 97
Nitric oxide furoxan derivative compounds endowed with antitumoral activity 97
Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. 97
Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. 95
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. 93
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. 93
Altered macrophage differentiation and immune dysfunction in tumor development. 92
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. 92
PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY 91
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages 91
Disabled homolog 2 controls pro-metastatic activity of tumor-associated macrophages 91
Antitumor vaccination: where we stand. 90
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. 90
Antigen specificity of immune suppression by myeloid-derived suppressor cells. 89
The Endless Saga of Monocyte Diversity 89
Deciphering the state of immune silence in fatal COVID-19 patients 88
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. 87
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. 87
CD66b-CD64dimCD115- cells in the human bone marrow represent neutrophil-committed progenitors 87
Gene expression profiling of human fibrocytic myeloid-derived suppressor cells (f-MDSCs) 85
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. 85
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. 85
Therapeutic targeting of myeloid-derived suppressor cells. 85
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. 85
Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. 85
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. 84
Use of myeloid cell biomarkers for the diagnosis of cancer. 84
Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. 83
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. 82
Baricitinib restrains the immune dysregulation in patients with severe COVID-19 82
Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. 81
Smoothing T cell roads to the tumor: Chemokine post-translational regulation. 81
Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis 81
Derangement of immune responses by myeloid suppressor cells. 80
Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. 80
Meccanismi molecolari della lisi mediata dai linfociti citotossici 80
Interaction of human pancreatic ductal adenocarcinoma cells with polymeric scaffolds to develop tissue-engineered cancer models. 80
Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression 80
Adoptive transfer of lymphokine-activated killer cells loaded with 4'-deoxy-4'-iododoxorubicin: therapeutic effect in mice bearing lung metastases. 79
A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells 79
Detection and functional evaluation of arginase-1 isolated from human PMNs and murine MDSC 79
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. 78
Role of adhesion molecules in the immune reaction to M-MSV-induced tumors. 78
Transcription factors in myeloid-derived suppressor cell recruitment and function. 78
Nitric oxide affects immune cells bioenergetics: long-term effects of nitric-oxide derivatives on leukaemic Jurkat cell metabolism 78
Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. 78
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. 78
Role of arginine metabolism in immunity and immunopathology. 76
Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic ApproachesNano-Oncologicals 76
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. 76
Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion 75
Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. 75
Immunogenetic aspects of erosive osteoarthritis of the hand in patients from northern Italy. 75
Inhibition of CTL-line lysis after gangliosides treatment. 75
Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. 75
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. 74
Bone marrow mesenchymal stromal cells induce nitric oxide synthase-dependent differentiation of CD11b+ cells that expedite hematopoietic recovery 74
The immune regulation in cancer by the amino acid metabolizing enzymes ARG and IDO. 74
Myeloid-derived suppressor cells generated in vitro 73
mTOR and STAT3 Pathway Hyper-Activation is Associated with evated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment 73
Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer 73
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. 72
Interaction of large granular lymphocytes with susceptible target does not induce second messenger and cytolytic granule exocytosis. 71
Extracellular ATP causes lysis of mouse thymocytes and activates a plasma membrane ion channel. 71
4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells 71
Tumor cells hijack macrophages via lactic acid 71
The in vivo role of leukocyte function-associated antigen-1 in cytotoxic cell activity against tumors induced by Moloney-murine sarcoma/leukemia retroviral complex. 70
Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. 70
Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+Monocytic Antigen-Presenting Cells in Tumors 70
The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia 70
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. 69
Therapeutical effect of 4'-deoxy-4'-iododoxorubicin-loaded LAK cells in mice bearing lung metastases. 69
Responses of mouse lymphocytes to extracellular adenosine 5'-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. 69
The pros and cons of chemokines in tumor immunology 69
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. 68
Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. 68
Totale 8.924
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.035
article - articoli 50.655
book - libri 0
conference - conferenze 1.145
curatela - curatele 0
other - altro 945
patent - brevetti 1.173
selected - selezionate 0
volume - volumi 3.117
Totale 114.070
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.129 0 0 0 0 90 155 88 222 39 181 132 222
2020/20211.748 101 273 65 188 324 164 23 132 151 37 203 87
2021/20221.735 106 442 31 52 74 47 70 111 115 89 151 447
2022/20232.728 257 262 303 445 230 632 42 154 294 14 57 38
2023/20241.516 63 98 101 192 209 236 66 140 16 87 239 69
2024/20251.635 275 271 146 710 233 0 0 0 0 0 0 0
Totale 15.603